@article {Wong2023.02.13.23285848, author = {Jessica Y. Wong and Justin K. Cheung and Yun Lin and Helen S. Bond and Eric H. Y. Lau and Dennis K. M. Ip and Benjamin J. Cowling and Peng Wu}, title = {Intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong}, elocation-id = {2023.02.13.23285848}, year = {2023}, doi = {10.1101/2023.02.13.23285848}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Understanding severity of infections with SARS-CoV-2 and its variants is crucial to inform public health measures. Here we used COVID-19 patient data from Hong Kong to characterise the severity profile of COVID-19 and to examine factors associated with fatality of infection.Methods Time-varying and age-specific effective severity measured by case-hospitalization risk and hospitalization risk was estimated with all individual COVID-19 case data collected in Hong Kong from 23 January 2020 through to 26 October 2022 over six epidemic waves, in comparison with estimates of influenza A(H1N1)pdm09 during the 2009 pandemic. The intrinsic severity of Omicron BA.2 was compared with the estimate for the ancestral strain with the data from unvaccinated patients without previous infections. Factors potentially associated with the fatality risk of hospitalized Omicron patients were also examined.Results With 32,222 COVID-19 hospitalizations and 9,669 deaths confirmed over 6 epidemic waves in Hong Kong, the time-varying hospitalization fatality risk dramatically increased from below 10\% before the largest fifth wave of Omicron BA.2, to 41\% during the peak of the fifth wave when hospital resources were severely constrained. The age-specific fatality risk in unvaccinated hospitalized Omicron cases was comparable to the estimates for unvaccinated cases with the ancestral strain. During epidemics predominated by Omicron BA.2, the highest fatality risk was amongst unvaccinated patients aged >=80 years and the risk was inversely associated with the number of vaccination doses received.Conclusions Omicron has comparable intrinsic severity to the ancestral Wuhan strain although the effective severity is substantially lower in Omicron cases due to vaccination. With a moderate-to-high coverage of vaccination, hospitalized COVID-19 patients caused by Omicron subvariants appeared to have similar age-specific risks of fatality to patients hospitalized with influenza A(H1N1)pdm09.Competing Interest StatementBJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Pfizer, Roche and Sanofi Pasteur. The other authors report no other potential conflicts of interest.Funding StatementThis project was supported by a commissioned grant from the Health and Medical Research Fund of the Hong Kong SAR Government (grant no. CID-HKU2-13), and the Collaborative Research Scheme (project no. C7123-20G) of the Research Grants Council of the Hong Kong SAR Government. BJC is supported by the RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China. The funding bodies had no role in the design of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study received ethical approval from the Institutional Review Board of the University of Hong KongI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRestrictions apply to the availability of these data. The hospitalization and mortality data are available for access with the permission from the Hospital Authority and the Census and Statistics Department of Hong Kong.}, URL = {https://www.medrxiv.org/content/early/2023/02/21/2023.02.13.23285848}, eprint = {https://www.medrxiv.org/content/early/2023/02/21/2023.02.13.23285848.full.pdf}, journal = {medRxiv} }